Robert Hardi

1.8k total citations
24 papers, 728 citations indexed

About

Robert Hardi is a scholar working on Genetics, Epidemiology and Anesthesiology and Pain Medicine. According to data from OpenAlex, Robert Hardi has authored 24 papers receiving a total of 728 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 10 papers in Epidemiology and 5 papers in Anesthesiology and Pain Medicine. Recurrent topics in Robert Hardi's work include Inflammatory Bowel Disease (10 papers), Microscopic Colitis (7 papers) and Anesthesia and Sedative Agents (5 papers). Robert Hardi is often cited by papers focused on Inflammatory Bowel Disease (10 papers), Microscopic Colitis (7 papers) and Anesthesia and Sedative Agents (5 papers). Robert Hardi collaborates with scholars based in United States, Belgium and Israel. Robert Hardi's co-authors include Ronald E. Pruitt, Kathleen M. Mullane, Erik R. Dubberke, Arnab Ray, Darrell S. Pardi, Robert Orenstein, Mayur Ramesh, Daniel J. Pambianco, John J. Vargo and James F. Martin and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Clinical Infectious Diseases.

In The Last Decade

Robert Hardi

22 papers receiving 711 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Hardi United States	10	291	242	203	166	128	24	728
T. Poralla Germany	19	382 1.3×	88 0.4×	220 1.1×	36 0.2×	92 0.7×	56	973
Dimitrios Polymeros Greece	16	217 0.7×	180 0.7×	330 1.6×	26 0.2×	119 0.9×	43	786
S Vavricka Switzerland	12	153 0.5×	236 1.0×	275 1.4×	60 0.4×	82 0.6×	27	649
B. B. Scott United Kingdom	12	304 1.0×	375 1.5×	168 0.8×	24 0.1×	68 0.5×	18	926
Yuan‐Hung Kuo Taiwan	22	634 2.2×	24 0.1×	407 2.0×	51 0.3×	168 1.3×	83	1.3k
Steven Polyak United States	12	147 0.5×	189 0.8×	102 0.5×	83 0.5×	142 1.1×	21	519
Fuad Hasan Kuwait	17	738 2.5×	137 0.6×	205 1.0×	34 0.2×	42 0.3×	59	1.1k
Stine Ydegaard Turiño Denmark	8	95 0.3×	160 0.7×	374 1.8×	35 0.2×	113 0.9×	9	678
Benjamin Koslowsky Israel	16	212 0.7×	237 1.0×	375 1.8×	59 0.4×	185 1.4×	53	803
Rosalind Sim United Kingdom	7	185 0.6×	248 1.0×	244 1.2×	32 0.2×	28 0.2×	9	632

Countries citing papers authored by Robert Hardi

Since Specialization

Citations

This map shows the geographic impact of Robert Hardi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Hardi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Hardi more than expected).

Fields of papers citing papers by Robert Hardi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Hardi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Hardi. The network helps show where Robert Hardi may publish in the future.

Co-authorship network of co-authors of Robert Hardi

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Hardi. A scholar is included among the top collaborators of Robert Hardi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Hardi. Robert Hardi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Graham, David Y., Saleh A. Naser, Thomas J. Borody, et al.. (2024). Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn’s Disease. Antibiotics. 13(8). 694–694. 3 indexed citations

Graham, David Y., Saleh A. Naser, Elliot Offman, et al.. (2019). 643 RHB-104, a Fixed-Dose, Oral Antibiotic Combination Against Mycobacterium Avium Paratuberculosis (MAP) Infection, Is Effective in Moderately to Severely Active Crohn's Disease. The American Journal of Gastroenterology. 114(1). S376–S377. 14 indexed citations

Berinstein, Jeffrey, Calen A. Steiner, Athos Bousvaros, et al.. (2019). The Clinical Accuracy of the BÜHLMANN fCAL ELISA in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome: A Multicenter Prospective Case–Control Study. Crohn s & Colitis 360. 1(3). 3 indexed citations

Dadkhah, Ezzat, Masoumeh Sikaroodi, Louis Y. Korman, et al.. (2019). Gut microbiome identifies risk for colorectal polyps. BMJ Open Gastroenterology. 6(1). e000297–e000297. 37 indexed citations

Hazan, Sabine, Gary Gottlieb, Keith Friedenberg, et al.. (2019). The validity of breath collection bags method in detecting Helicobacter pylori using the novel BreathID^®Hp Lab System: a multicenter clinical study in 257 subjects. SHILAP Revista de lepidopterología. 12. 3244448329–3244448329. 4 indexed citations

DeMicco, Michael, Lucy Clayton, Michael S. Epstein, et al.. (2017). Novel 1 L polyethylene glycol-based bowel preparation NER1006 for overall and right-sided colon cleansing: a randomized controlled phase 3 trial versus trisulfate. Gastrointestinal Endoscopy. 87(3). 677–687.e3. 62 indexed citations

Quigley, Eamonn M.M., Michael Camilleri, Yishai Ron, et al.. (2017). A Comparison of the Efficacy and Safety of 2 Dosing Regimens, 2 and 5 Times per Week, of an Intraluminal Vibrating Capsule in the Management of Chronic Idiopathic Constipation. The American Journal of Gastroenterology. 112. S226–S226. 1 indexed citations

Orenstein, Robert, Erik R. Dubberke, Robert Hardi, et al.. (2015). Safety and Durability of RBX2660 (Microbiota Suspension) for RecurrentClostridium difficileInfection: Results of the PUNCH CD Study. Clinical Infectious Diseases. 62(5). 596–602. 161 indexed citations

Korman, Louis Y., et al.. (2015). Sa1499 Randomized Trial of Effect of Propofol vs Moderate Sedation on Colonoscopy Force Generation: an Interim Analysis. Gastrointestinal Endoscopy. 81(5). AB239–AB239.

10.

Osterman, Mark T., Faten Aberra, Raymond K. Cross, et al.. (2014). Mesalamine Dose Escalation Reduces Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 12(11). 1887–1893.e3. 65 indexed citations

11.

Hardi, Robert, et al.. (2014). Enema Administration of RBX2660 (Microbiota Suspension) for Recurrent C. difficile Infection: Lessons Learned from the PUNCH CD Study. The American Journal of Gastroenterology. 109. S192–S193. 1 indexed citations

12.

Osterman, Mark T., Faten Aberra, Robert P. McCabe, et al.. (2014). 862 A Randomized Controlled Trial of Mesalamine Dose Escalation for Ulcerative Colitis in Remission. Gastroenterology. 146(5). S–149. 2 indexed citations

13.

Mayer, Lloyd, William J. Sandborn, Karel Geboes, et al.. (2013). Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 63(3). 442–450. 119 indexed citations

14.

Kaufman, Barry, Robert Hardi, Ronald E. Pruitt, et al.. (2012). Novel STAT3 Selective Inhibitor Natura-α Shows Great Promises in Treating Moderate-to-severe Ulcerative Colitis in a Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial. The American Journal of Gastroenterology. 107. S638–S638. 1 indexed citations

15.

Pambianco, Daniel J., John J. Vargo, Ronald E. Pruitt, Robert Hardi, & James F. Martin. (2010). Computer-assisted personalized sedation for upper endoscopy and colonoscopy: a comparative, multicenter randomized study. Gastrointestinal Endoscopy. 73(4). 765–772. 86 indexed citations

16.

Abreu, María T., Christian von Tirpitz, Robert Hardi, et al.. (2009). Extracorporeal photopheresis for the treatment of refractory Crohnʼs disease: Results of an open-label pilot study. Inflammatory Bowel Diseases. 15(6). 829–836. 30 indexed citations

17.

Hardi, Robert, Lloyd Mayer, Stephan R. Targan, et al.. (2008). 704 A Phase 1 Open-Label, Single-Dose, Dose-Escalation Study of Mdx-1100, a High-Affinity, Neutralizing, Fully Human Igg1κ Anti-CXCL10 (Ip10) Monoclonal Antibody, in Ulcerative Colitis. Gastroenterology. 134(4). A–99. 5 indexed citations

18.

Aue, Georg, Nancy M. Carroll, Bruce Kressel, Robert Hardi, & McDonald K. Horne. (2005). Disseminated intravascular coagulation in an ambulatory young woman. Journal of Laboratory and Clinical Medicine. 146(3). 192–196. 3 indexed citations

19.

Pruitt, Ronald E., John S. Hanson, Michael Safdi, et al.. (2002). Balsalazide Is Superior to Mesalamine in the Time to Improvement of Signs and Symptoms of Acute Mild-to-Moderate Ulcerative Colitis. The American Journal of Gastroenterology. 97(12). 3078–3086. 85 indexed citations

20.

Pruitt, Ronald E., John S. Hanson, Michael Safdi, et al.. (2000). Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute ulcerative colitis. Gastroenterology. 118(4). A120–A121. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact